Top Page
Life Science Reit Plc
(LSE:LABS)
Life Science Reit Plc (LABS) vs. iShares MSCI United Kingdom ETF (EWC)
Life Science Reit Plc Business Overview & Revenue Model
Life Science Reit Plc Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | -5.63M | 19.94M | 15.71M | 532.00K |
| Gross Profit | -5.63M | 10.44M | 7.15M | 77.00K |
| EBITDA | 9.78M | 8.72M | -65.04M | -302.00K |
| Net Income | -13.98M | -21.71M | -27.61M | 7.74M |
Balance Sheet | ||||
| Total Assets | 401.19M | 410.70M | 447.82M | 361.40M |
| Cash, Cash Equivalents and Short-Term Investments | 5.57M | 14.34M | 45.61M | 165.96M |
| Total Debt | 122.24M | 107.92M | 109.83M | 0.00 |
| Total Liabilities | 138.42M | 126.96M | 128.37M | 10.82M |
| Stockholders Equity | 262.77M | 283.75M | 319.45M | 350.58M |
Cash Flow | ||||
| Free Cash Flow | -6.36M | -16.42M | -8.73M | 3.54M |
| Operating Cash Flow | 12.92M | 7.62M | -1.09M | 3.54M |
| Investing Cash Flow | -16.35M | -11.64M | -186.38M | -181.52M |
| Financing Cash Flow | -5.34M | -27.24M | 67.11M | 343.94M |
Life Science Reit Plc Technical Analysis
Life Science Reit Plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | £484.34M | 11.61 | 7.68% | 5.63% | 1.73% | 21.53% | |
73 Outperform | ― | ― | 4.41% | ― | |||
68 Neutral | £247.49M | 81.61 | 1.05% | 6.56% | ― | ― | |
63 Neutral | C$2.00B | 5.80 | -0.84% | 5.13% | 1.83% | -19.11% | |
58 Neutral | £134.75M | ― | -5.11% | 5.17% | 1.84% | 35.65% | |
58 Neutral | £270.01M | 9.66 | 6.76% | 2.05% | -19.90% | ― | |
53 Neutral | £199.49M | 78.06 | 0.71% | 35.42% | -7.28% | ― |
Life Science Reit Plc Corporate Events
Life Science REIT PLC, a UK-based real estate investment trust, announced that BlackRock, Inc. has crossed the 5% threshold in its voting rights, now holding a total of 5% in the company. This acquisition of voting rights by a major investment firm like BlackRock could signify increased investor confidence and potentially impact the company’s strategic decisions and market positioning.
Spark’s Take on GB:LABS Stock
According to Spark, TipRanks’ AI Analyst, GB:LABS is a Neutral.
Life Science REIT Plc’s overall score reflects financial instability and valuation concerns, partially offset by positive technical indicators and proactive corporate strategies. Key strengths include a debt-free balance sheet and recent leasing successes, while profitability and cash flow remain significant risks.
To see Spark’s full report on GB:LABS stock, click here.
Life Science REIT plc has announced the distribution of its 2024 Annual Report and the Notice of its 2025 Annual General Meeting (AGM) to shareholders who opted for hard copies. These documents have also been submitted to the Financial Conduct Authority’s National Storage Mechanism. The AGM is scheduled to take place on 3 June 2025 at Ironstone Asset Management’s offices in London. This announcement ensures compliance with UK Listing and Disclosure Guidance and Transparency Rules, reinforcing the company’s commitment to transparency and regulatory adherence.
Spark’s Take on GB:LABS Stock
According to Spark, TipRanks’ AI Analyst, GB:LABS is a Neutral.
Life Science REIT Plc’s overall score reflects financial instability and valuation concerns, partially offset by positive technical indicators and proactive corporate strategies. Key strengths include a debt-free balance sheet and recent leasing successes, while profitability and cash flow remain significant risks.
To see Spark’s full report on GB:LABS stock, click here.
Life Science REIT PLC, a UK-based real estate investment trust, has announced a change in the voting rights held by BlackRock, Inc. BlackRock’s voting rights in Life Science REIT have fallen below 5%, indicating a reduction in their stake. This change in voting rights could impact the company’s shareholder dynamics and influence future decision-making processes.
Spark’s Take on GB:LABS Stock
According to Spark, TipRanks’ AI Analyst, GB:LABS is a Neutral.
Life Science REIT Plc’s overall score reflects financial instability and valuation concerns, partially offset by positive technical indicators and proactive corporate strategies. Key strengths include a debt-free balance sheet and recent leasing successes, while profitability and cash flow remain significant risks.
To see Spark’s full report on GB:LABS stock, click here.
Life Science REIT plc has announced a strategic review to explore options for maximizing shareholder value, prompted by challenges such as high inflation, elevated interest rates, and low liquidity, which have led to a prolonged discount in share price. Despite these challenges, the company has made progress in leasing activities and cost-saving measures, with a focus on capturing rental growth and completing development projects, while future dividends are suspended pending the review’s outcome.
Life Science REIT has signed a new lease agreement with Oxford Expression Technologies Limited at Oxford Technology Park, setting a new rental high for the park. This agreement highlights the company’s commitment to catering to emerging life science businesses by providing flexible and specialized spaces. The lease will bring the total estimated rental value captured since September 2024 to £1.5 million, emphasizing the company’s strategic positioning in the life sciences property market. The move by OET to the park signifies the growing demand for bespoke facilities that support the development and success of life science companies.
Life Science REIT PLC announced that BlackRock, Inc., a major shareholder, has increased its voting rights in the company to 5% as of April 8, 2025. This acquisition of voting rights by BlackRock signifies a strengthened position in the company, potentially impacting its governance and strategic decisions, and reflects confidence in the company’s market positioning within the life sciences real estate sector.
Life Science REIT PLC, a UK-based real estate investment trust, announced a change in major holdings as BlackRock, Inc., a global investment management corporation, has adjusted its voting rights in the company to below 5%. This adjustment in BlackRock’s holdings indicates a shift in its investment strategy, which could have implications for the company’s market perception and investor confidence.
Life Science REIT plc has revised its investment advisory agreement with Ironstone Asset Management Limited, changing the fee calculation basis from net asset value to the lower of net asset value and average market capitalisation. This adjustment, effective from April 2025, is expected to save the company £1.0 million annually, enhancing earnings per share by 0.3 pence. The revisions also remove the requirement for Ironstone to acquire shares in relation to 15% of the advisory fee, potentially impacting the company’s financial dynamics and stakeholder interests.
Life Science REIT PLC announced a change in major holdings as Rathbones Investment Management Ltd adjusted its voting rights, now holding 14.98% down from 15.87%. This shift in voting rights indicates a slight reduction in influence by Rathbones, which may impact future strategic decisions or shareholder dynamics within the company.
Life Science REIT plc has announced a strategic review to explore options for maximizing shareholder value, including a potential sale or managed wind down, amid challenges like high inflation and interest rates affecting the REIT sector. The company has suspended dividends due to delays in leasing activity and is negotiating reduced fees with its investment advisor to better align interests with shareholders. The strategic review will include a formal sale process, with Panmure Liberum appointed as the financial adviser, but there is no certainty of an offer being made.
Life Science REIT plc has announced a significant leasing deal at its Cambourne Park Science & Technology Campus in Cambridge, further solidifying its position as a key player in the life sciences real estate market. The company has successfully let 17,200 sq ft to 42 Technology Limited, a consultancy specializing in technical solutions across various sectors, marking a critical step in repositioning Cambourne Park as a premier science and technology hub. This lease increases occupancy to 83% and demonstrates the company’s effective strategy in attracting life sciences and technology businesses, enhancing its asset value and market positioning.
Life Science REIT has successfully leased 5,100 sq ft of laboratory space at Rolling Stock Yard in London to CFDX Ltd, marking full occupancy of the building. This move highlights the company’s ability to meet the precise needs of leading life science firms and taps into the strong demand for quality lab spaces in prime locations, reinforcing its strategic position in the UK life science property market.